Stock REKA REKAH PHARMACEUTICAL INDUSTRY LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Rekah Pharmaceutical Industry Ltd.

Equities

REKA

IL0010810096

Pharmaceuticals

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 07:24:09 2024-04-25 EDT 		5-day change 1st Jan Change
1,311 ILa -4.10% Intraday chart for Rekah Pharmaceutical Industry Ltd. -1.87% -11.30%
03-26 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Rekah Pharmaceutical Industry Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 293.9 228 305.9 265.7 175.7 168.7
Enterprise Value (EV) 1 346.5 342 435.3 412.9 321.1 335.2
P/E ratio 41.7 x 57.2 x 28.3 x 40.1 x -85.5 x -24.2 x
Yield - - - 3.73% - -
Capitalization / Revenue 1.41 x 1.16 x 1.15 x 1.01 x 0.6 x 0.52 x
EV / Revenue 1.67 x 1.74 x 1.64 x 1.56 x 1.1 x 1.04 x
EV / EBITDA 13.7 x 14 x 12.4 x 13.7 x 9.28 x 12.9 x
EV / FCF -217 x -92.6 x -40.7 x -2,008 x 9.66 x 33.2 x
FCF Yield -0.46% -1.08% -2.45% -0.05% 10.4% 3.01%
Price to Book 1.94 x 1.47 x 1.85 x 1.54 x 1.08 x 1.08 x
Nbr of stocks (in thousands) 11,415 11,415 11,415 11,415 11,415 11,415
Reference price 2 25.75 19.97 26.80 23.28 15.39 14.78
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-30 23-03-29 24-03-26
1ILS in Million2ILS
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 207.8 196.5 265.5 264 292.4 321.7
EBITDA 1 25.38 24.45 35.17 30.09 34.61 26.03
EBIT 1 14.63 12.6 20.89 12.91 13.25 2.906
Operating Margin 7.04% 6.41% 7.87% 4.89% 4.53% 0.9%
Earnings before Tax (EBT) 1 9.918 4.543 14.16 7.71 0.357 -7.05
Net income 1 7.005 3.987 10.8 6.624 -2.041 -6.91
Net margin 3.37% 2.03% 4.07% 2.51% -0.7% -2.15%
EPS 2 0.6181 0.3493 0.9459 0.5800 -0.1800 -0.6100
Free Cash Flow 1 -1.6 -3.694 -10.68 -0.2056 33.25 10.09
FCF margin -0.77% -1.88% -4.02% -0.08% 11.37% 3.14%
FCF Conversion (EBITDA) - - - - 96.06% 38.78%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - 0.8678 - -
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-30 23-03-29 24-03-26
1ILS in Million2ILS
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 52.6 114 129 147 145 166
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.071 x 4.665 x 3.68 x 4.891 x 4.201 x 6.395 x
Free Cash Flow 1 -1.6 -3.69 -10.7 -0.21 33.2 10.1
ROE (net income / shareholders' equity) 4.64% 1.8% 6.73% 3.91% -1.22% -4.35%
ROA (Net income/ Total Assets) 3.07% 2.36% 3.32% 1.88% 1.87% 0.39%
Assets 1 228.1 168.9 325.3 351.6 -109.1 -1,775
Book Value Per Share 2 13.30 13.60 14.50 15.20 14.20 13.60
Cash Flow per Share 2 2.780 2.240 3.230 1.630 1.770 1.690
Capex 1 15.2 43.1 18.6 13.5 6.93 11.5
Capex / Sales 7.3% 21.94% 7.02% 5.11% 2.37% 3.57%
Announcement Date 19-03-28 20-03-31 21-03-22 22-03-30 23-03-29 24-03-26
1ILS in Million2ILS
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Pharmaceuticals Wholesale

1st Jan change Capi.
REKAH PHARMACEUTICAL INDUSTRY LTD. Stock Rekah Pharmaceutical Industry Ltd.
-11.30% 39.24M
MCKESSON CORPORATION Stock McKesson Corporation
+16.45% 71.39B
CARDINAL HEALTH, INC. Stock Cardinal Health, Inc.
+1.92% 25.1B
SINOPHARM GROUP CO. LTD. Stock Sinopharm Group Co. Ltd.
-1.22% 8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD Stock Shanghai Pharmaceuticals Holding Co., Ltd
+7.95% 8.19B
HUADONG MEDICINE CO., LTD Stock Huadong Medicine Co., Ltd
-20.48% 7.91B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD Stock Jointown Pharmaceutical Group Co., Ltd
+15.26% 4.31B
EBOS GROUP LIMITED Stock EBOS Group Limited
-1.24% 3.93B
GALENICA AG Stock Galenica AG
-3.02% 3.86B
CHINA NATIONAL MEDICINES CORPORATION LTD. Stock China National Medicines Corporation Ltd.
+21.10% 3.64B
Pharmaceuticals Wholesale
  1. Stock Market
  2. Equities
  3. REKA Stock
  4. Financials Rekah Pharmaceutical Industry Ltd.